SCHEMBL7006348

SCHEMBL7006348

N#Cc1ccccc1S(=O)(=O)NCCCCCCNc1nsc2nccn12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 10/20 0.74
TGM1 P22735 4/20 0.69
NPY5R Q15761 4/20 0.38
SLC40A1 Q9NP59 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
RECQL P46063 1/20 0.35
AGTR1 P30556 1/20 0.35
AGTR2 P50052 1/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7014440 0.86 F13A1 (0.80) F13A1TGM1NPY5RKDM4EALDH1A1
SCHEMBL7007005 0.85 F13A1 (0.75) F13A1TGM1NPY5RKDM4EALDH1A1
SCHEMBL7006075 0.85 F13A1 (0.78) F13A1TGM1NPY5RKDM4EALDH1A1
SCHEMBL7008678 0.85 F13A1 (1.00) F13A1TGM1NPY5RALDH1A1RECQL
SCHEMBL7009337 0.85 F13A1 (0.78) F13A1TGM1NPY5RKDM4EALDH1A1
SCHEMBL7010031 0.85 F13A1 (0.78) F13A1TGM1NPY5RKDM4EALDH1A1
SCHEMBL7007806 0.84 F13A1 (1.00) F13A1TGM1KDM4EALDH1A1HTR1A
SCHEMBL7002927 0.83 F13A1 (0.76) F13A1TGM1
SCHEMBL7002753 0.83 F13A1 (0.75) F13A1TGM1NPY5RKDM4EALDH1A1
SCHEMBL7006157 0.83 F13A1 (0.71) F13A1TGM1KDM4EALDH1A1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases APOTEX INC. 2003-12-04 US disclosed
EP-1348710-A1 Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases Apotex Inc. (CA) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases PIGS, FGB, SERPINE1 F13A1 14/4885TGM1 7/4885NPY5R 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.